{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:35:34Z","timestamp":1794270934592,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NIH P30 CA023100"],"award-info":[{"award-number":["NIH P30 CA023100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5U01CA180888-08"],"award-info":[{"award-number":["5U01CA180888-08"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tertiary lymphoid structures (TLSs) facilitate tumor microenvironment immune interactions. While TLSs and their associated gene signatures correlate with better response to immune checkpoint inhibitors (ICIs), the complex transcriptomic interplay\/co-regulation among these factors remains under investigation. We analyzed correlations between survival and transcriptome expression (35 immunoregulatory factors associated with B\/T cells and TLSs) in 217 patients with ICI-treated solid tumors. Denser correlations among B\/T cell markers, immune checkpoints, and TLS-related molecules was associated with longer survival. High CXCL13 (B-lymphocyte chemoattractant) expression correlated with longer overall survival (hazard ratio [HR] 0.46 [95% CI: 0.27\u20130.81],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006) in 217 ICI-treated patients but not in 272 ICI-na\u00efve patients (HR 0.85 [0.52\u20131.40],\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.519), suggesting its potential predictive\/ICI-related, rather than prognostic, value. Overall, patients with highly coordinated T- and B-cell activity, checkpoints, and TLS-related molecules, and higher CXCL13 expression demonstrated prolonged survival after ICIs. Comprehensive multiomics and tumor immunomic profiling may better predict outcome after immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01427-9","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:51Z","timestamp":1777374531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Yu","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DePietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RJ","family":"Seager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadakatsu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1427_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 186, 1652\u20131669 (2023).","journal-title":"Cell."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer. 24, 498\u2013512 (2024).","journal-title":"Nat. Rev. Cancer."},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14, 847\u2013856 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.36401\/JIPO-22-9","volume":"5","author":"NJ Bevins","year":"2022","unstructured":"Bevins, N. J. et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy. J. Immunother. Precis Oncol. 5, 90\u201397 (2022).","journal-title":"J. Immunother. Precis Oncol."},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. Development of immunotherapy combination strategies in cancer. Cancer Discov. 11, 1368\u20131397 (2021).","journal-title":"Cancer Discov."},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.CIR-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides, M. et al. Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol. Res. 10, 372\u2013383 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1427_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00743-4","volume":"12","author":"AM Goodman","year":"2020","unstructured":"Goodman, A. M. et al. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 12, 45 (2020).","journal-title":"Genome Med."},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"1550341","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2019","unstructured":"Boichard, A. et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology 8, 1550341 (2019).","journal-title":"Oncoimmunology"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/1878-0261.12748","volume":"14","author":"TV Pham","year":"2020","unstructured":"Pham, T. V. et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol. Oncol. 14, 1680\u20131694 (2020).","journal-title":"Mol. Oncol."},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai, S., Itahashi, K. & Nishikawa, H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat. Rev. Clin. Oncol. 21, 337\u2013353 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1427_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman, W. H., Zitvogel, L., Saut\u00e8s-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717\u2013734 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2159-8290.CD-20-0962","volume":"11","author":"MF Sanmamed","year":"2021","unstructured":"Sanmamed, M. F. et al. A burned-out CD8(+) T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy. Cancer Discov. 11, 1700\u20131715 (2021).","journal-title":"Cancer Discov."},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8(+) T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1427_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109632","volume":"27","author":"Y Fujiwara","year":"2024","unstructured":"Fujiwara, Y. et al. High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy. iScience 27, 109632 (2024).","journal-title":"iScience"},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman, W. H. et al. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity 56, 2254\u20132269 (2023).","journal-title":"Immunity"},{"key":"1427_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"1427_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep00765","volume":"2","author":"JL Messina","year":"2012","unstructured":"Messina, J. L. et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).","journal-title":"Sci. Rep."},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541.e525 (2022).","journal-title":"Immunity"},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"Y Hayashi","year":"2023","unstructured":"Hayashi, Y. et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br. J. Cancer 128, 2175\u20132185 (2023).","journal-title":"Br. J. Cancer"},{"key":"1427_CR27","doi-asserted-by":"publisher","unstructured":"Gorvel, L. et al. Tertiary lymphoid structures are associated with enhanced macrophage activation and immune checkpoint expression, and predict outcome in cervical cancer. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.Cir-24-0979 (2025).","DOI":"10.1158\/2326-6066.Cir-24-0979"},{"key":"1427_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41392-024-01947-5","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances. Signal Transduct. Target. Ther. 9, 225 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"1427_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/0008-5472.CAN-23-3325","volume":"84","author":"G Petroni","year":"2024","unstructured":"Petroni, G., Pillozzi, S. & Antonuzzo, L. Exploiting tertiary lymphoid structures to stimulate antitumor immunity and improve immunotherapy efficacy. Cancer Res. 84, 1199\u20131209 (2024).","journal-title":"Cancer Res."},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466\u2013489 (2023).","journal-title":"Cancer Cell"},{"key":"1427_CR32","doi-asserted-by":"publisher","unstructured":"Goswami, S. et al. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.abc4220 (2020).","DOI":"10.1126\/scitranslmed.abc4220"},{"key":"1427_CR33","doi-asserted-by":"publisher","unstructured":"Okamura, R. et al. ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2019-000438 (2020).","DOI":"10.1136\/jitc-2019-000438"},{"key":"1427_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102287","volume":"100","author":"J Mullen","year":"2021","unstructured":"Mullen, J., Kato, S., Sicklick, J. K. & Kurzrock, R. Targeting ARID1A mutations in cancer. Cancer Treat. Rev. 100, 102287 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"1427_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004669","volume":"10","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, N., Kato, S., Lippman, S. & Kurzrock, R. Chromatin remodeling (SWI\/SNF) complexes, cancer, and response to immunotherapy. J. Immunother. Cancer 10, e004669 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1427_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jmoldx.2017.10.001","volume":"20","author":"JM Conroy","year":"2018","unstructured":"Conroy, J. M. et al. Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors. J. Mol. Diagn. 20, 95\u2013109 (2018).","journal-title":"J. Mol. Diagn."},{"key":"1427_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41525-023-00359-8","volume":"8","author":"H Miyashita","year":"2023","unstructured":"Miyashita, H. et al. T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. NPJ Genom. Med. 8, 19 (2023).","journal-title":"NPJ Genom. Med."},{"key":"1427_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102942","volume":"9","author":"D Nishizaki","year":"2024","unstructured":"Nishizaki, D. et al. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers. ESMO Open 9, 102942 (2024).","journal-title":"ESMO Open"},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/2326-6066.CIR-18-0517","volume":"7","author":"HH Workel","year":"2019","unstructured":"Workel, H. H. et al. A transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol. Res 7, 784\u2013796 (2019).","journal-title":"Cancer Immunol. Res"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01427-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:17:00Z","timestamp":1783034220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01427-9","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.F. reports expenses from Conquer Cancer, the ASCO Foundation, American Association for Cancer Research, and Japanese Medical Society of America. S.K. serves as a consultant for Medpace, Foundation Medicine, NeoGenomics, and CureMatch. He receives speaker\u2019s fee from Roche and Bayer, and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta, OmniSeq, and Personalis. T.J., P.D., and R.J.S. are employees of LabCorp. R.K. has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, OmniSeq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and\/or speaker fees and\/or advisory board\/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2\/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. The other authors do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}